Research records indexed for Mazdutide
This page carries 12 of the 58 records that the literature query returned for Mazdutide, selected by citation count and preferring records that name the compound in their title. It is a selection, not a complete index, and the 46 records it does not carry are not represented here. Every row resolves to a real identifier and names the study model, so no finding reads as a human claim by default. The compound page is Mazdutide.
Indexed records
| Record | Year | Study type | Model | n as stated | What it reported |
|---|---|---|---|---|---|
| Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes pmid:41407860 | 2026 | Clinical Trial, Phase III, Comparative Study | human trial | Not stated | Indexed as clinical trial, phase iii, comparative study. study model from MeSH "Humans" with publication type "clinical trial, phase iii". subject headings: Diabetes Mellitus, Type 2; Body Weight; Peptides; Recombinant Fusion Proteins; Hypoglycemic Agents. |
| Mazdutide versus placebo in Chinese adults with type 2 diabetes pmid:41407859 | 2026 | Clinical Trial, Phase III, Research Support, Non-U.S. Gov't | human trial | Not stated | Indexed as clinical trial, phase iii, research support, non-u.s. gov't. study model from MeSH "Humans" with publication type "clinical trial, phase iii". subject headings: Diabetes Mellitus, Type 2; Weight Loss; Blood Glucose; Peptides; Receptors, Glucagon. |
| Mazdutide 9 mg in Chinese adults with a body mass index ≥30 kg/m<sup>2</sup> but without diabetes: A phase 2 randomized controlled trial pmid:41875890 | 2026 | Clinical Trial, Phase II, Randomized Controlled Trial | human trial | Not stated | Indexed as clinical trial, phase ii, randomized controlled trial. study model from MeSH "Humans" with publication type "clinical trial, phase ii". subject headings: Obesity; Weight Loss; Peptides; Anti-Obesity Agents; Body Mass Index. |
| Mazdutide versus Semaglutide for the treatment of type 2 diabetes and obesity: Rationale, design and baseline data of DREAMS-3 phase 3 trial pmid:41260459 | 2026 | Clinical Trial Protocol | other | Not stated | Indexed as clinical trial protocol. study model from MeSH "Humans" with no interventional publication type. subject headings: Diabetes Mellitus, Type 2; Obesity; Weight Loss; Metformin; Blood Glucose. |
| Efficacy and Safety of the Dual Glucagon-Like Peptide-1 and Glucagon Receptor Agonist Mazdutide in Predominantly Chinese Adults With Obesity and/or Type 2 Diabetes: A Systematic Review and Meta-Analysis pmid:42410325 | 2026 | Meta-Analysis, Systematic Review | other | Not stated | Indexed as meta-analysis, systematic review. study model from MeSH "Humans" with no interventional publication type. subject headings: Diabetes Mellitus, Type 2; Obesity; Body Weight; Weight Loss; Peptides. |
| Efficacy and Safety of Mazdutide in Managing Overweight and Obesity Among Non-Diabetic Adults: A Meta-Analysis of Randomised Controlled Trials pmid:41804840 | 2026 | Meta-Analysis, Review | other | Not stated | Indexed as meta-analysis, review. study model from MeSH "Humans" with no interventional publication type. subject headings: Obesity; Weight Loss; Peptides; Anti-Obesity Agents; Hypoglycemic Agents. |
| Patent landscape and therapeutic evolution of mazdutide: a dual GLP-1/Glucagon receptor agonist for obesity and type 2 diabetes pmid:41820018 | 2026 | Review | other | Not stated | Indexed as review. study model from MeSH "Animals" with no rodent species heading. subject headings: Diabetes Mellitus, Type 2; Obesity; Peptides; Receptors, Glucagon; Anti-Obesity Agents. |
| Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity: The GLORY-2 Randomized Clinical Trial pmid:42251595 | 2026 | Clinical Trial, Phase III, Multicenter Study | human trial | Not stated | Indexed as clinical trial, phase iii, multicenter study. study model from MeSH "Humans" with publication type "clinical trial, phase iii". subject headings: Diabetes Mellitus, Type 2; Obesity; Body Weight; Weight Loss; Diarrhea. |
| Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight pmid:40421736 | 2025 | Clinical Trial, Phase III, Multicenter Study | human trial | Not stated | Indexed as clinical trial, phase iii, multicenter study. study model from MeSH "Humans" with publication type "clinical trial, phase iii". subject headings: Obesity; Weight Loss; Peptides; Receptors, Glucagon; Anti-Obesity Agents. |
| Mazdutide, a dual agonist targeting GLP-1R and GCGR, mitigates diabetes-associated cognitive dysfunction: mechanistic insights from multi-omics analysis pmid:40479843 | 2025 | research-article | rodent | Not stated | Indexed as research-article. study model from MeSH "Mice". subject headings: Brain; Diabetes Mellitus, Type 2; Disease Models, Animal; Peptides; Receptors, Glucagon. |
| Mazdutide reduces body weight in adults with overweight or obesity: A high-dose Phase 1 trial pmid:40832785 | 2025 | research-article, Clinical Trial, Phase I | human trial | Not stated | Indexed as research-article, clinical trial, phase i. study model from MeSH "Humans" with publication type "clinical trial, phase i". subject headings: Obesity; Body Weight; Weight Loss; Peptides; Anti-Obesity Agents. |
| Mazdutide: First Approval pmid:41028652 | 2025 | Review | other | Not stated | Indexed as review. study model from MeSH "Humans" with no interventional publication type. subject headings: Diabetes Mellitus, Type 2; Obesity; Peptides; Receptors, Glucagon; Anti-Obesity Agents. |
Where this page sits
Compound page: Mazdutide. Class: Incretin receptor agonists.
Retrieved 2026-10-12.
Sources
- PubChem Compound Summary for CID 167312357, Mazdutide. PubChem, National Library of Medicine (2026). pubchem:167312357
- Drugs@FDA application register query for this compound, no application records returned. U.S. Food and Drug Administration, openFDA drugsfda endpoint (2026). fda:mazdutide
- IBI362 (LY3305677), a weekly-dose GLP-1 and glucagon receptor dual agonist, in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple ascending dose phase 1b study. EClinicalMedicine (2021). pmid:34430840
- A phase 1b randomised controlled trial of a glucagon-like peptide-1 and glucagon receptor dual agonist IBI362 (LY3305677) in Chinese patients with type 2 diabetes. Nature communications (2022). pmid:35750681
- Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple-ascending-dose phase 1b trial. EClinicalMedicine (2022). pmid:36247927
- A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity. Nature communications (2023). pmid:38092790
- Efficacy and Safety of Mazdutide in Chinese Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial. Diabetes care (2024). pmid:37943529
- Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight. The New England journal of medicine (2025). pmid:40421736
- Mazdutide versus placebo in Chinese adults with type 2 diabetes. Nature (2026). pmid:41407859
- Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes. Nature (2026). pmid:41407860
- Efficacy and safety of Mazdutide on weight loss among diabetic and non-diabetic patients: a systematic review and meta-analysis of randomized controlled trials. Frontiers in endocrinology (2024). pmid:38440786
On each stated value was matched to the record cited for it. That is record matching, not an appraisal of the research. Compiled and checked by: Peptide Monographs editorial desk. No qualified clinical reviewer.